AngioDynamics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANGO research report →
About the company
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets.
- CEO
- James C. Clemmer
- IPO
- 2004
- Employees
- 748
- HQ
- Latham, NY, US
Price Chart
- Market Cap
- $540.86M
- P/E
- -17.35
- P/S
- 1.72
- P/B
- 3.14
- EV/EBITDA
- -92.42
- Div Yield
- 0.00%
- Gross Margin
- 53.45%
- Op Margin
- -8.08%
- Net Margin
- -10.00%
- ROE
- -17.65%
- ROIC
- -13.03%
- Revenue
- $292.50M · -3.76%
- Net Income
- $-33,993,000 · 81.56%
- EPS
- $-0.83 · 81.92%
- Op Income
- $-39,954,000
- FCF YoY
- 56.99%
- 52W High
- $13.99
- 52W Low
- $8.36
- 50D MA
- $11.72
- 200D MA
- $11.51
- Beta
- 0.34
- Avg Volume
- 372.91K
Get TickerSpark's AI analysis on ANGO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 21, 25 | Weiss Lawrence T | buy | 10,000 |
| Oct 13, 25 | Trowbridge Stephen A | buy | 890 |
| Oct 9, 25 | Clemmer James C | buy | 10,000 |
| Jul 19, 25 | Trowbridge Stephen A | other | 2,585 |
| Jul 20, 25 | Trowbridge Stephen A | other | 717 |
| Jul 21, 25 | Trowbridge Stephen A | other | 667 |
| Jul 19, 25 | Piccinini Laura | other | 1,983 |
| Jul 20, 25 | Piccinini Laura | other | 616 |
| Jul 19, 25 | Nighan Warren JR | other | 735 |
| Jul 20, 25 | Nighan Warren JR | other | 251 |
Our ANGO coverage
Recent articles, reports, and earnings notes.
No research on ANGO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANGO report →Similar companies
Peers in the same neighborhood.